Design, synthesis, anticancer evaluation and molecular docking studies of 1,2,3-triazole incorporated 1,3,4-oxadiazole-Triazine derivatives
Sujana Oggu,
Parameswari Akshinthala,
Naresh Kumar Katari,
Laxmi Kumari Nagarapu,
Srimannarayana Malempati,
Rambabu Gundla,
Sreekantha Babu Jonnalagadda
Affiliations
Sujana Oggu
Department of Chemistry, GITAM School of Science, GITAM (Deemed to be University), Hyderabad, Telangana, 502 329, India; G. Narayanamma Institute of Technology & Science, Hyderabad, Telangana, 500 104, India
Parameswari Akshinthala
Department of Science and Humanities, MLR Institute of Technology, Dundigal, Medchal, Hyderabad, Rudraram, 500043, India
Naresh Kumar Katari
Department of Chemistry, GITAM School of Science, GITAM (Deemed to be University), Hyderabad, Telangana, 502 329, India; School of Chemistry & Physics, College of Agriculture, Engineering & Science, Westville Campus, University of KwaZulu-Natal, P Bag X 54001, Durban, 4000, South Africa
Laxmi Kumari Nagarapu
Department of Chemistry, GITAM School of Science, GITAM (Deemed to be University), Hyderabad, Telangana, 502 329, India
Srimannarayana Malempati
Department of Chemistry, GITAM School of Science, GITAM (Deemed to be University), Hyderabad, Telangana, 502 329, India; Corresponding author.
Rambabu Gundla
Department of Chemistry, GITAM School of Science, GITAM (Deemed to be University), Hyderabad, Telangana, 502 329, India; Corresponding author.
Sreekantha Babu Jonnalagadda
School of Chemistry & Physics, College of Agriculture, Engineering & Science, Westville Campus, University of KwaZulu-Natal, P Bag X 54001, Durban, 4000, South Africa; Corresponding author.
A new library of 1,2,3-triazole-incorporated 1,3,4-oxadiazole-triazine derivatives (9a-j) was designed, synthesized, and tested in vitro for anticancer activity against PC3 and DU-145 (prostate cancer), A549 (lung cancer), and MCF-7 (breast cancer) cancer cell lines using the MTT assay with etoposide as the control drug. The compounds exhibited remarkable anticancer activity, with IC50 values ranging from 0.16 ± 0.083 μM to 11.8 ± 7.46 μM, whereas the positive control ranged from 1.97 0.45 μM to 3.08 0.135 μM. Compound 9 d with a 4-pyridyl moiety shown exceptional anticancer activity against PC3, A549, MCF-7, and DU-145 cell lines, with IC50 values of 0.17 ± 0.063 μM, 0.19 ± 0.075 μM, 0.51 ± 0.083 μM, and 0.16 ± 0.083 μM, respectively.
